Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125865802 | 12586580 | 2 | F | 201511 | 20160919 | 20160725 | 20160929 | PER | US-PFIZER INC-2016224221 | PFIZER | 69.00 | YR | F | Y | 102.00000 | KG | 20160929 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125865802 | 12586580 | 1 | PS | IBRANCE | PALBOCICLIB | 1 | Oral | 125 MG, CYCLIC (TAKE ON DAYS 1-21 OUT OF A 28 DAYS CYCLE) | 207103 | 125 | MG | CAPSULE | |||||||
| 125865802 | 12586580 | 2 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | 125 MG, CYCLIC (ONCE DAILY FOR 21 DAYS THEN OFF 7 DAYS) | 207103 | 125 | MG | CAPSULE | |||||||
| 125865802 | 12586580 | 3 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | 125 MG, CYCLIC (DAILY DAYS 1-21 Q 28) | 207103 | 125 | MG | CAPSULE | |||||||
| 125865802 | 12586580 | 4 | SS | FASLODEX | FULVESTRANT | 1 | LOADING DOSES EVERY TWO WEEKS TIMES THREE | 0 | INJECTION | ||||||||||
| 125865802 | 12586580 | 5 | SS | FASLODEX | FULVESTRANT | 1 | Intramuscular | 500 MG, MONTHLY (1ST DAY OF IBRANCE CYCLE) | 0 | 500 | MG | INJECTION | /month | ||||||
| 125865802 | 12586580 | 6 | SS | FASLODEX | FULVESTRANT | 1 | Intramuscular | 500 MG, CYCLIC(Q 28 D) | 0 | 500 | MG | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125865802 | 12586580 | 1 | Breast cancer metastatic |
| 125865802 | 12586580 | 4 | Breast cancer metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125865802 | 12586580 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125865802 | 12586580 | Anaemia | |
| 125865802 | 12586580 | Arthralgia | |
| 125865802 | 12586580 | Fatigue | |
| 125865802 | 12586580 | Movement disorder | |
| 125865802 | 12586580 | Neoplasm progression | |
| 125865802 | 12586580 | Neutropenia | |
| 125865802 | 12586580 | Off label use | |
| 125865802 | 12586580 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125865802 | 12586580 | 2 | 201511 | 0 | ||
| 125865802 | 12586580 | 3 | 2016 | 0 | ||
| 125865802 | 12586580 | 5 | 201511 | 0 | ||
| 125865802 | 12586580 | 6 | 2016 | 0 |